{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:35:30Z","timestamp":1793500530538,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Disseminated nontuberculous mycobacteria (NTM) infections occur mostly in immunocompromised patients. Therefore, it is difficult to diagnose disseminated NTM infections in patients without history of immunocompromised diseases or using immunosuppressant. Patients with anti-interferon-\u03b3 (IFN-\u03b3) autoantibodies are vulnerable to intracellular infections, such as disseminated NTM. Currently, there is no widely used and efficient technique for the detection of anti-IFN-\u03b3 autoantibodies. Herein, we report a case of an apparently healthy patient with disseminated <jats:italic>Mycobacterium avium<\/jats:italic> complex (MAC) infection who tested positive for anti-IFN-\u03b3 autoantibodies.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 64-year-old non-immunocompromised and apparently healthy Asian male presented to the emergency department with complaints of progressive chest pain for about 6\u2009months and weight loss. A bulging tumour was found in the anterior chest wall. Chest computed tomography showed a lung mass over the right lower lobe and an osteolytic lesion with a soft tissue component at the sternum. Sonography-guided biopsies for the osteolytic lesion and sputum culture confirmed the presence of disseminated MAC infection. In addition, positive test result of anti-IFN-\u03b3 autoantibodies was noted. The patient was prescribed antibiotics. The lesions over the right lower lobe and sternum attenuated following the antibiotic treatment.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Detection of anti-IFN-\u03b3 autoantibodies is important among previously healthy people with disseminated NTM infection. Presence of anti-IFN-\u03b3 autoantibodies may suggest a high risk of severe intracellular infection, such as disseminated NTM infection.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-019-4564-4","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T20:44:43Z","timestamp":1572468283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Disseminated Mycobacterium avium complex infection mimicking malignancy in a patient with anti-IFN-\u03b3 autoantibodies: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Yun-Kai","family":"Yeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ya","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Lung","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"key":"4564_CR1","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.rmed.2009.04.026","volume":"103","author":"GJ Ballarino","year":"2009","unstructured":"Ballarino GJ, Olivier KN, Claypool RJ, et al. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med. 2009;103:1448\u201355.","journal-title":"Respir Med"},{"issue":"3","key":"4564_CR2","doi-asserted-by":"publisher","first-page":"e0003623","DOI":"10.1371\/journal.pntd.0003623","volume":"9","author":"Y Shao","year":"2015","unstructured":"Shao Y, Chen C, Song H, et al. The epidemiology and geographic distribution of nontuberculous mycobacteria clinical isolates from sputum samples in the eastern region of China. PLoS Negl Trop Dis. 2015;9(3):e0003623.","journal-title":"PLoS Negl Trop Dis"},{"key":"4564_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1089\/jir.2013.0050","volume":"34","author":"N Ramirez-Alejo","year":"2014","unstructured":"Ramirez-Alejo N, Santos-Argumedo L. Innate defects of the IL-12\/IFN-c axis in susceptibility to infections by mycobacteria and salmonella. J Interf Cytokine Res. 2014;34:307\u201317.","journal-title":"J Interf Cytokine Res"},{"key":"4564_CR4","doi-asserted-by":"publisher","first-page":"e3927","DOI":"10.1097\/MD.0000000000003927","volume":"95","author":"CY Chi","year":"2016","unstructured":"Chi CY, Lin CH, Ho MW, et al. Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-\u03b3 autoantibodies and disseminated nontuberculous mycobacterial infections. Medicine (Baltimore). 2016;95:e3927. \n                    https:\/\/doi.org\/10.1097\/MD.0000000000003927\n                    \n                  .","journal-title":"Medicine (Baltimore)"},{"key":"4564_CR5","first-page":"210","volume":"6","author":"MM Johnson","year":"2014","unstructured":"Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. J Thorac Dis. 2014;6:210\u201320.","journal-title":"J Thorac Dis"},{"key":"4564_CR6","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3201\/eid2206.151860","volume":"22","author":"F Valour","year":"2016","unstructured":"Valour F, Perpoint T, S\u00e9n\u00e9chal A, et al. Interferon-\u03b3 autoantibodies as predisposing factor for nontuberculous mycobacterial infection. Emerg Infect Dis. 2016;22:1124\u20136.","journal-title":"Emerg Infect Dis"},{"key":"4564_CR7","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","volume":"2","author":"CS Haworth","year":"2017","unstructured":"Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;2:ii1\u2013ii64.","journal-title":"Thorax"},{"key":"4564_CR8","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/00002030-199610090-00014","volume":"10","author":"C Fordham von Reyn","year":"1996","unstructured":"Fordham von Reyn C, Arbeit RD, Tosteson AN, et al. The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS. International MAC Study Group. AIDS. 1996;10:1025.","journal-title":"AIDS"},{"issue":"4","key":"4564_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"4564_CR10","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1182\/blood-2012-08-452482","volume":"121","author":"CY Chi","year":"2013","unstructured":"Chi CY, Chu CC, Liu JP, Lin CH, Ho MW, Lo WJ, et al. Anti-IFN-gamma autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection. Blood. 2013;121(8):1357\u201366 pmid:23243276.","journal-title":"Blood"},{"issue":"5102","key":"4564_CR11","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1126\/science.8456301","volume":"259","author":"S Huang","year":"1993","unstructured":"Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, Kamijo R, et al. Immune response in mice that lack the interferon-gamma receptor. Science. 1993;259(5102):1742\u20135.","journal-title":"Science"},{"key":"4564_CR12","first-page":"543","volume":"64","author":"S Norouzi","year":"2012","unstructured":"Norouzi S, Aghamohammadi A, Mamishi S, Rosenzweig SD, Rezaei N. Bacillus Calmette-Guerin (BCG) complications associated with primary immunodeficiency diseases. J Inf Secur. 2012;64:543\u201354.","journal-title":"J Inf Secur"},{"issue":"7","key":"4564_CR13","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.4049\/jimmunol.175.7.4769","volume":"175","author":"SY Patel","year":"2005","unstructured":"Patel SY, Ding L, Brown MR, et al. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol. 2005;175(7):4769\u201376.","journal-title":"J Immunol"},{"issue":"17","key":"4564_CR14","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1182\/blood-2011-12-395707","volume":"119","author":"SK Browne","year":"2012","unstructured":"Browne SK, Zaman R, Sampaio EP, Jutivorakool K, Rosen LB, Ding L, et al. Anti-CD20 (rituximab) therapy for anti-IFN-gamma autoantibody-associated nontuberculous mycobacterial infection. Blood. 2012;119(17):3933\u20139.","journal-title":"Blood"},{"issue":"1","key":"4564_CR15","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1086\/380453","volume":"38","author":"R Doffinger","year":"2004","unstructured":"Doffinger R, Helbert MR, Barcenas-Morales G, et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis. 2004;38(1):e10\u20134.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"4564_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood-2003-04-1065","volume":"103","author":"C Hoflich","year":"2004","unstructured":"Hoflich C, Sabat R, Rosseau S, et al. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood. 2004;103(2):673\u20135.","journal-title":"Blood"},{"issue":"25","key":"4564_CR17","doi-asserted-by":"publisher","first-page":"e3927","DOI":"10.1097\/MD.0000000000003927","volume":"95","author":"CY Chi","year":"2016","unstructured":"Chi CY, Lin CH, Ho MW, Ding JY, Huang WC, Shih HP, et al. Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-gamma autoantibodies and disseminated nontuberculous mycobacterial infections. Medicine (Baltimore). 2016;95(25):e3927.","journal-title":"Medicine (Baltimore)"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4564-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4564-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4564-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:11:48Z","timestamp":1603843908000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4564-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4564"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4564-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,29]]},"assertion":[{"value":"26 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Witten informed consent was obtained from the patient for publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"909"}}